Since 2020, the Center for Health Equity in Surgery and Anesthesia has used research, education and advocacy to improve access to safe surgical, anesthetic and perioperative care in underserved areas of the U.S. and globally, as well as build a pipeline of care providers from diverse backgrounds.
John Clements, MD, whose scientific discoveries helped save millions of newborns around the world from respiratory distress syndrome and whose boundless appetite for learning helped create the interdisciplinary culture at UCSF, has died on Sept. 3, 2024 at the age of 101.
A new study is projecting that the number of people in the U.S. with atrial fibrillation, a common precursor to stroke, is about three times higher than previous estimates. An estimated 35% of people with a-fib will have a stroke.
UCSF researchers identify new metabolic biomarkers that could indicate higher risk for Sudden Infant Death Syndrome (SIDS) in infants.
An extra-long summer surge driven by new variants has prompted the early release of updated COVID-19 vaccines. A UCSF expert tells us what new vaccines could mean for the summer surge, who should get vaccinated, and when/where to get your vaccines.
UCSF is collaborating with the SF Palliative Care Work Group to set up partnerships with local community groups to discuss advance care planning and palliative care. These community groups include churches, senior centers and organizations representing minority populations.
For the 2024-2025 academic year, UCSF School of Dentistry extends its Community Based Clinical Education to third-year students, previously limited to fourth-year learners.
Scientists discover how to drug GTPases, a group of 150 critical enzymes that act like "switches" in cells, which cause a wide variety of diseases such as cancer and Parkinson’s disease when mutated.
For more than 30 years, UCSF has run a 10-week summer internship program for 40-54 health/life sciences undergraduates. Students are assigned to a lab at UCSF and conduct research, which they present at the end of the program.
A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start.
